Sorafenib is a multiple kinase inhibitor whose mechanism is to inhibit the Raf / MEK / ERK [i.e., the extracellular signal-regulated kinase (ERK) pathway] signaling to decrease the tumor growth and angiogenesis, and to induce the tumor cell apoptosis (23–25). Here, MAP2K7 is linked to neoplasm.